Yes, no new insights there from what we've already suspected/discussed about the S1 subgrouping. And the author overstates his case a bit on safety; the company cites ARIAs just to make a point.
His overall view is the company will be compelled to run a bigger confirmatory trial(s) before possible approval.
Market Data 
Markets 
AI
